Sun
Pharma secures DGCI approval for breast cancer drug
Sun Pharma Advanced Research Company has received the approval from Drug Controller General of India (DGCI) for its medicine to be used for the treatment of breast cancer. The company‘s medicine, Paclitaxel Injection Concentrate for Nano dispersion (PICN), was found to be equally effective and safe when compared to Abraxane in a clinical study.
The drug has been approved by the regulator both in the 260mg/m2 and 95mg/m2 doses to be administered every 3 weeks. This medicine offers the convenience of a quick and easy one-step dilution and infusion preparation for healthcare professionals. It can be administered in a short 30 minute infusion and unlike conventional Paclitaxel formulations it does not require pre-medication with steroids and anti-histamines. Also, this drug doesn’t lead to any significant hypersensitivity reaction in patients.
Sun Pharma Advanced Research Company has received the approval from Drug Controller General of India (DGCI) for its medicine to be used for the treatment of breast cancer. The company‘s medicine, Paclitaxel Injection Concentrate for Nano dispersion (PICN), was found to be equally effective and safe when compared to Abraxane in a clinical study.
The drug has been approved by the regulator both in the 260mg/m2 and 95mg/m2 doses to be administered every 3 weeks. This medicine offers the convenience of a quick and easy one-step dilution and infusion preparation for healthcare professionals. It can be administered in a short 30 minute infusion and unlike conventional Paclitaxel formulations it does not require pre-medication with steroids and anti-histamines. Also, this drug doesn’t lead to any significant hypersensitivity reaction in patients.
No comments:
Post a Comment